Gsk (GLAXF) Receivables - Other (2016 - 2025)

Gsk's Receivables - Other history runs 10 years deep, the most recent figure standing at $1.5 billion for Q4 2025.

• In Q4 2025, Receivables - Other rose 38.7% year-over-year to $1.5 billion; the TTM figure through Dec 2025 stood at $1.5 billion (up 38.7% YoY), while the FY2025 annual figure was $1.5 billion, up 38.05% from the prior year.
• Receivables - Other was $1.5 billion for Q4 2025 at Gsk, up from $1.1 billion in the prior quarter.
• In the past five years, Receivables - Other ranged from a high of $15.2 billion in Q1 2022 to a low of $1.1 billion in Q4 2024.
• Historically, Receivables - Other has averaged $3.7 billion across 5 years, with a median of $1.5 billion in 2022.
• The sharpest annual moves came in 2022 and 2025: Receivables - Other declined 15.74% in 2022, then surged 38.7% in 2025.
• A 5-year view of Receivables - Other shows it stood at $1.7 billion in 2021, then declined by 15.74% to $1.4 billion in 2022, then retreated by 9.81% to $1.3 billion in 2023, then decreased by 15.19% to $1.1 billion in 2024, then jumped by 38.7% to $1.5 billion in 2025.
• The last three Receivables - Other figures came in at $1.5 billion (Q4 2025), $1.1 billion (Q4 2024), and $1.3 billion (Q4 2023), per Business Quant data.